This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Original Article -
Joint effect among p53, CYP1A1, GSTM1 polymorphism combinations and smoking on prostate cancer risk: an exploratory genotype-environment interaction study
Luis A. Quiñnes1, Carlos E. Irarráabal1, Claudio R. Rojas1, Cristian E. Orellana1, Cristian Acevedo2, Christian Huidobro2, Nelson E. Varela1, Dante D. Cáeres3
1Laboratory of Chemical Carcinogenesis and Pharmacogenetics, Faculty of Medicine, Biomedical Science Institute (ICBM), University of Chile, Independencia 1027, Santiago, Chile
2Department of Urology, National Cancer Corporation, Chile, Capell Abarz 027, Providencia, Santiago, Chile
3Epidemiology Division, School of Public Health, Faculty of Medicine, University of Chile, Independencia 939, Santiago, Chile
Abstract
Aim: To assess the role of several genetic factors in combination with an environmental factor as modulators of
prostate cancer risk. We focus on allele variants of low-penetrance genes associated with cell control, the
detoxification processes and smoking.
Methods: In a case-control study we compared people carrying
p53cd72 Pro allele, CYP1A1
M1 allele and GSTM1 null genotypes with their prostate cancer risk.
Results: The joint risk for smokers carrying
Pro* and M1*, Pro* and
GSTM1null or GSTM1 null and
CYP1A1 M1* variants was significantly higher
(odds ratio [OR]: 13.13, 95% confidence interval [CI]: 2.41-1.36; OR: 3.97, 95% CI: 1.13-3.95 and OR: 6.87,
95% CI: 1.68-7.97, respectively) compared with that for the reference group, and for non-smokers
was not significant. OR for combinations among
p53cd72, GSTM1 and CYP1A1 M1 in smokers were positively and significantly associated
with prostate cancer risk compared with non-smokers and compared with the putative lowest risk group (OR: 8.87,
95% CI: 1.25-2.71). Conclusion: Our results suggest that a combination of
p53cd72, CYP1A1, GSTM1 alleles and smoking plays a significant role in modified prostate cancer risk on the study population, which means that smokers
carrying susceptible genotypes might have a significantly higher risk than those carrying non-susceptible genotypes.
(Asian J Androl 2006 May; 8: 349-355)
Keywords: p53cd72; GSTM1;
Correspondence to:Dr Dante D. Cáeres, Epidemiology Division, School of Public Health, University of Chile, Independencia 939,
Santiago, Chile.
Tel: +56-2-678-6396, Fax: +56-2-737-7121
E-mail: dcaceres@med.uchile.cl
Received 2005-10-06 Accepted 2005-12-23
1 Introduction
Prostate cancer (PCa) is one of the most frequent malignant neoplasms in men; however, the rate of this disease
shows remarkable worldwide variation. Many studies indicate that environmental and genetic factors play a
significant role in the etiology of this disease [1,2]. Given the multicausal etiology of PCa, synergistic interactions among
genetic and other risk factors might have significant effects on PCa risk, especially gene-gene
(G×G) and gene-environment
(G×E) interactions. It is well known that in the carcinogenic process there are multiple points at which
genetically-determined host characteristics and/or environmental factors might influence individual susceptibility, through
effects on metabolic activation, DNA-repair capacity, and other cellular processes. Polymorphic genes implicated in
cancer etio-logy can have significant effects on increasing or redu-cing differential susceptibility to environmental
cancer [3].
The p53 gene is one of the most mutated tumor-suppressor genes in human neoplasms, and it has been referred
as the "emergency brake gene" because of its tumor-preventing apoptotic and cell-cycle-checkpoint functions in
physiologically stressful situations [4]. The wild type
p53 gene polymorphism at codon 72
(p53cd72) produces a protein with an arginine
(Arg: CGC) or proline (Pro: CCC) genotype. This polymorphism related to changes in the
function of the p53 protein is strongly associated with the tumor formation process. The wild-type
p53 gene suppresses cellular transformation with activated oncogenes, therefore inhibiting the growth of malignant cells [5].
In contrast, human cytochrome P450 (CYP) phase I enzymes function in a wide variety of metabolic pathways
involving endogenous and exogenous compounds, such as steroids and environmental xenobiotics. The
CYP1A1 gene encodes by benzo(a)pyrene hydroxylase and it is primarily expressed in the liver but has also been detected in
prostate tissue [6]. CYP1A1 activates benzo-(a)pyrene into epoxides and phenolic products that are mutagenic and
carcinogenic; therefore, higher catalytic activity might predispose patients to cancer risk by increasing carcinogenic
compounds in target sites such as the prostate and lung tissues [6, 7]. Three restriction fragment length polymorphic
(RFLP) variants have received the most attention:
MspI RFLP (CYP1A1*2A), MspI RFLP
(CYP1A1*2C) and (CYP1A1*3). The rare
Val and M2 alleles of the CYP1A1
gene might increase individual cancer risk by heightening
aryl hydrocarbon hydroxylase (AHH) enzyme inducibility [8]. Alternatively, among the phase II enzymes involved in
the metabolism of xenobiotic compounds the
GST family catalyze the conjugation of glutathione to numerous
potentially genotoxic compounds, including aliphatic aromatic he- terocyclic radicals, epoxides, or arene oxides. Individual
differences in the detoxification of reactive chemicals through the
GST pathways are frequently the result of deletion
of the GST genes, particularly GSTM1 and
GSTT1 [9]. Individuals who have inherited susceptible variants (homozygous
deletions of GSTM1 or GSTT1) of the metabolizing genes might have an increased body burden of reactive metabolites
from cigarette smoke, causing increased risk of the development of PCa [10, 11]. However, contradictory findings
have been reported in recent studies [12-15].
It is possible that individual variations in biotransformation activities on both phase I and phase II enzymes in
coordination with p53 activity regulate the effect of DNA toxic metabolites and might be partially responsible for host
susceptibility to chemical exposure, which is related to PCa.
Our overall aim in the present study is to assess the role of several genetic factors in combination with an
environment factor as modulators of PCa risk by focusing on allele variants of low-penetrance genes associated with
cell control and detoxification processes, and smoking. We determine the relationships between
GSTM1 deletion, Msp1 CYP1A1 polymorphism, p53cd72
polymorphism and smoking on PCa risk.
2 Materials and methods
2.1 Sample subjects
Cases for this study were recruited in a voluntary screening performed in Santiago¡¯s Metropolitan Area, Chile, by
the National Cancer Corporation. Prostate specific antigen (PSA) and digital rectal examination (DRE) were carried
out by urologists [16]. All people with suspected PCa (PSA=4mg/dL or altered DRE, or both) were biopsied and
histologically confirmed. A total of 60 PCa cases and 117 controls were included in the present study. The controls
were men attending the respiratory service of the Clinical Hospital of University of Chile, with similar demographic
characteristics to the PCa cases. All study subjects provided informed consent for participation in this research under
a protocol approved by the Ethics Committee for Studies on Human Beings at the University of Chile.
2.2 Blood samples
Blood samples were collected from all of the participants at time of inclusion. The samples were processed at the
Laboratory of Chemical Carcinogenesis and Pharmacogenetics at the Faculty of Medicine of the University of Chile to
obtain genomic DNA from peripheral leucocytes using the method of Miller [17]. The genomic DNA was checked for
purity at 260/280mm absorption and re-purified with phenol/chloroform protocol if required. DNA was stored at
-30°C until use.
2.3 Genotyping methods
After DNA extraction, DNA samples were analyzed for
GSTM1, CYP1A1 and p53 genetic polymorphisms.
Polymerase chain reaction (PCR) based RFLP was used to examine the polymorphisms of interest. All samples were
submitted to separate amplifications followed by digestion with restriction enzymes.
2.4 Polymerase chain reaction (PCR) amplification detection
For the CYP1A1 MspI site, PCR amplification was carried out using previously described primers C44 and C47
yielding a fragment of 340 bp [7]. GSTM1
null variant was determined using primers described by Ambrosone
et al. [18] simultaneously with Msp1 primers as internal control for amplification.
p53cd72 genetic polymorphism was determined using the primers described by de la Calle-Martin
et al. [19]. The different genotypes were observed
using 2% agarose or 6% polyacrylamide gel electrophoresis.
2.5 Nomenclature used to genetic polymorphisms
The following nomenclature was used to describe the different polymorphic variants [20]. For the
p53cd72 polymorphisms the possible genotypes are
Pro/Pro, Arg/Pro and Arg/Arg. For the
CYP1A1*2A, the reference allele is called wild type
(Wt), and rare allele is called M1. The
GSTM1 1*/1* and GSTM1 1*/*2 are referred to as
present variant (homozygous and heterozygous), with
GSTM1 2*/*2 genotype used to indicate the homozygous
null variant. For GST, null and present denominations will be used. From this point forward,
M1* and Pro* will be used for
Wt/M1, M1/M1, and Pro/Pro
and Arg/Pro genotypes, with the objective to increase precision.
2.6 Analytic methodology
Genotype frequencies and 95% confidence interval (CI) for
GSTM1 were calculated as the proportion of
individuals with a given genotype divided by the total number of participants. For
p53cd72 and CYP1A1, allele frequencies
and 95% CI were calculated as the number of alleles divided by the number of chromosomes, and the test for
Hardy-Weinberg equilibrium was conducted. To explore the possible associations between
GSTM1, CYP1A1 and p53cd72 genetic polymorphisms and PCa risk, and to evaluate the putative modification by these genotypes of the effect of
smoking, we cross-classified the data using a 2 by 4 table, as described by different authors, for a case-control design
[21]. The relationship between these
polymorphic genes and smoking and PCa risk was examined using odds ratio
(OR), with 95% CI using Woolf¡¯s method in an unconditional logistic model. All associations were evaluated using a
priori low-risk bivariate genotype combinations
(Arg/Arg, Wt/Wt and GSTM1 present) in non-smokers as a common
reference group. Finally, the ORs are presented unadjusted and adjusted by age. All statistical analyses were
performed with stata version 7.0 software (STATA Corporation; College Station, TX, USA).
3 Results
Characteristics of participants, genotype and allelic frequencies and OR for these polymorphisms and PCa in the
present study are described in Table2. Both the PCa and the control groups had a similar age distribution. Smoking
frequency was higher in the PCa cases compared with that in the controls and PCa cases had a
significant risk of PCa compared with the controls (OR:
2.59, 95% CI: 1.35-4.95). Allele frequencies for the
Pro and M1 allele were higher in the PCa cases compared with that in the controls. We did not find significant differences in genotype frequencies for
GSTM1 and CYP1A1 between the PCa cases and the controls subjects. A higher prevalence of
Pro/Pro genotype in the PCa cases compared with that in the control subjects was observed. ORs for
PCa associated with GSTM1
and CYP1A1 genotypes were close to the null value. For the different genotypes of
p53cd72, only Pro/Pro genotype was
positively associated with PCa (OR: 2.89, 95% CI: 1.17-7.10). We did not observe significant departures from the
Hardy-Weinberg equilibrium from p53cd72 and
CYP1A1 genotypes among the PCa cases
(P=0.356; P=0.096) or the controls
(P=0.621; P=0.706), respectively.
Table2 shows the results of the distribution of the joint effect between gene-gene polymorphisms and
smoking risk factor on PCa. The joint age-adjusted OR for smokers carrying
Pro* and M1* variants was 13.13 (95% CI:
2.41-71.36) and for non-smokers was 2.25 (95% CI:
0.44-13.48), compared with the reference group
(Arg/Arg=Wt/Wt=non-smokers
). In contrast, those smokers and non-smokers carrying only
Pro* variants had a lower, non-significant risk (OR:
4.16, 95% CI: 0.75-22.96 and
OR: 1.51, 95% CI: 0.21-10.59). However, smokers carrying
M1* and Arg/Arg genotypic variants had a higher
significant risk compared with the reference group (OR: 8.74, 95% CI: 1.58-48.39), but was not significant in
non-smokers (OR: 2.71, 95% CI: 0.48-15.35). The joint age-adjusted OR for smokers carrying
Pro* and GSTM1 null polymorphism was 3.97 (95% CI: 1.13-13.95) and for non-smokers was 0.80 (95% CI: 0.19-3.28) compared with
the reference group (Arg/Arg=GSTM1
null=non-smokers). Conversely, those smokers carrying
Pro* and GSTM1 present variants had a significant risk, 3.07 (95% CI: 1.01-9.37), but non-smokers had a non-significant risk, 0.95
(95% CI: 0.28-3.19). Smokers carrying
Arg/Arg and GSTM1 null genotypes showed an increased but
non-significant risk compared with the reference group (OR: 4.73, 95% CI: 0.89-5.18). Similarly, the risk for non-smokers
was not significant (OR: 0.57, 95% CI: 0.10-3.29). However, the joint effect between the
GSTM1 null and CYP1A1 M1* in smokers was significantly associated with PCa risk: 6.87 (95% CI: 1.68-27.97). In contrast, in non-smokers
the risk was not significant: 1.37 (95% CI: 0.35-5.46). The age-adjusted OR for smokers carrying the
GSTM1 null and Wt/wt genotypes were high but not significant: 2.69 (95% CI: 0.52-14.08). Those subjects carrying
GSTM1 present and M1* genotypes had a significant Pca risk for smokers but not for non-smokers (OR: 5.00, 95% CI:
1.47-17.05 and OR: 1.29, 95% CI: 0.36-4.58, respectively).
We performed the test of homogeneity for p53cd72-CYP1A1, p53cd72-GSTM1, GSTM1-CYP1A1
and smoking status, which clearly indicated that the Mantel-Henszel
OR for Pca differs depending on whether an individual smoked and on polymorphisms
combinations (OR: 3.44, 95% CI: 1.79-6.62; OR: 1.68, 95% CI: 0.98-2.56;
OR: 1.86, 95% CI: 1.11-3.11, respectively).
4 Discussion
The p53 Pro allele has recently been reported to be associated with genetically determined susceptibility to
smoking-related lung cancer in the Chilean population
[22]. Few studies have reported an association of
p53cd72 polymorphism with PCa risk [23,24], however the findings have been inconsistent. Phase I enzymes on cytochrome P450 (CYP) is
the major enzyme system in xenobiotic metabolism and plays a critical role in metabolic activation of many
environmental chemicals. Together with phase II metabolizing enzymes on glutathione S-transferase (GST) are responsible
for detoxification process, even though they might also be involved in bioactivation of some carcinogenic compounds.
This is true in the case of polycyclic aromatic hydrocarbons (PAH), which are important carcinogenic components of
tobacco smoke. Individual variation in the genes encoding these enzymes could be modifying the effect of specific
environmental risk factors and, therefore, could influence susceptibilities to cancer [25].
In this study, we used a case-control design to assess the joint effects of
p53cd72, CYP1A1, GSTM1 polymorphism and smoking habit on PCa risk. We observed that those subjects who are smokers carrying high-risk genotypic
variants have an increased PCa risk compared with non-carrying susceptible variant subjects. In general terms,
smoking has a synergistic effect on overall risk, which can be explained by the carcinogenic compounds of cigarette
smoke that can be differentially biotransformed by
CYP1A1 and/or GSTM1 (e.g. benzo-[a]pyrene).
The increased risks observed for smokers carrying susceptible genotypes of
CYP1A1 and p53 (OR: 13.13),
GSTM1 and p53 (OR: 3.97), and
CYP1A1 and GSTM1 (OR: 6.87) might be explained by the metabolic function of
these biotransformation enzymes, which might act in a coordinated but contrary pathway. Whereas
CYP1A1 produces the reactive benzo(a)pyrene diol epoxide, which can initiate a tumoral process,
GSTM1 detoxifies it by GSH conjugation [6, 26]. However, people who have
M1 allele and GSTM1 deletion cannot properly detoxify the
carcinogenic metabolites. This situation could be worse if
p53 function is decreased or deleted, which apparently occurs
with the p53cd72 Pro allele [27]. Our results support this asseveration (OR: 8.87, 95% CI:
1.25-62.71). In contrast, there is evidence that
benzo(a)-pyrene diol epoxide is able to inactivate
p53 antioncogen, providing indirect evidence of the potential relationship between
CYP1A1 and GSTM1 biotransformation enzymes and
p53 antioncogen [27]. An interesting additional research hypothesis is related to the role of
CYP1A1 and GSTM1 in steroid metabolism,
taking account the structural similarities between these hormones and PAH, and the participation of testosterone in
prostate cancer. This issue can explain, in part, the observed positive associations with the
CYP1A1 gene, even though this topic should be further investigated.
A limitation of the present study is the small numbers of cases of PCa. Hence, it is likely that the relationships
between these polymorphisms and smoking can be explained by chance. Therefore, the presence of positive
associations for CYP1A1, GSTM1 and
p53 polymorphisms in smokers and PCa risk must be determined in a bigger study.
In conclusion, our results suggest that a combination of
p53cd72, CYP1A1, GSTM1 genetic polymorphisms and
smoking play a significant role in modified prostate cancer risk on the study population, which means that smokers
carrying susceptible genotypes might have a significantly higher risk of PCa than those carrying non-susceptible
genotypes.
Acknowledgment
The National Cancer Corporation of Chile supported this work. We thank Dr Jorge Soto for reviewing this
manuscript.
References
1 Adami SL. Prostate Cancer. In: Hans-Olov Adami DH, Trichopoulos D, editors. Textbook of Cancer Epidemiology. New York:
Oxford University Press, 2002; p400-28.
2 Coughlin, SS, Hall IJ. A review of genetic polymorphisms and prostate cancer risk. Ann Epidemiol 2002; 12: 182-96.
3 Daly AK, Fairbrother KS, Smart J. Recent advances in understanding the molecular basis of polymorphisms in genes encoding
cytochrome P450 enzymes. Toxicol Lett 1998; 102-103: 143-7.
4 Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-31.
5 Greenblatt, MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suprressor gene: clues to cancer etiology and
molecular pathogenesis. Cancer Res 1994; 54: 4855-78.
6 Agundez JA, Martinez C, Olivera M, Gallardo L, Ladero JM, Rosado C,
et al. Expression in human prostate of drug- and
carcinogen-metabolizing enzymes: association with prostate cancer risk. Br J Cancer 1998; 78: 1361-7.
7 Quiñnes L, Lucas D, Godoy J, Cáeres D, Berthou F, Varela N,
et al. CYP1A1, CYP2E1 and GSTM1
genetic polymorphisms. The effect of single and combined
genotypes on lung cancer susceptibility in Chilean people. Cancer Lett 2001; 174: 35-44.
8 Hirvonen, A. Combinations of susceptible genotypes and individual responses to toxicants. Environ Health Perspect 1997; 105
(Suppl 4): 755-8.
9 Seidegard J, Vorachek WR, Pero RW, Pearson WR. Hereditary differences in the expression of the human glutathione transferase active
on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci USA 1988; 85: 7293-7.
10 Nakazato H, Suzuki K, Matsui H, Koike H, Okugi H, Ohtake N,
et al. Association of genetic polymorphisms of
glutathione-S-transferase genes (GSTM1,
GSTT1 and GSTP1) with familial prostate cancer risk in a Japanese population. Anticancer Res 2003; 23:
2897-902.
11 Ferreira PM, Medeiros R, Vasconcelos A, Costa S, Pinto D, Morais A,
et al. Association between CYP2E1 polymorphisms and
susceptibility to prostate cancer. Eur J Cancer Prev 2003; 12: 205-11.
12 Kidd LC, Woodson K, Taylor PR, Albanes D, Virtamo J, Tangrea JA. Polymorphisms in glutathione-S-transferase genes
(GST-M1, GST-T1 and GST-P1) and susceptibility to prostate cancer among male smokers of the ATBC cancer prevention study. Eur J Cancer
Prev 2003; 12: 317-20.
13 Gsur A, Haidinger G, Hinteregger S, Bernhofer G, Schatzl G, Madersbacher S,
et al. Polymorphisms of glutathione-S-transferase genes
(GSTP1, GSTM1 and GSTT1) and prostate-cancer risk. Int J Cancer 2001; 95: 152-5.
14 Kote-Jarai Z, Easton D, Edwards SM, Jefferies S, Durocher F, Jackson
RA, et al. CRC/BPG UK Familial Prostate Cancer Study
Collaborators.Relationship between glutathione S-transferase M1, P1 and T1 polymorphisms and early onset prostate cancer.
Pharmacogenetics 2001; 11: 325-30.
15 Rebbeck TR, Walker AH, Jaffe JM, White DL, Wein AJ, Malkowicz SB. Glutathione S-transferase-mu
(GSTM1) and -theta (GSTT1) genotypes in the etiology of prostate cancer. Cancer Epidemiol Biomarkers Prev 1999; 8 (4 Pt 1): 283-7.
16 Acevedo C, Opazo JL, Huidobro C, Cabezas J, Iturrieta J, Quinones Sepulveda L. Positive correlation between single or combined
genotypes of CYP1A1 and GSTM1 in relation to prostate cancer in Chilean people. Prostate 2003; 57: 111-7.
17 Miller SA, Dykes DD, Polesky HF. A simple salting out
procedure for extracting DNA from human nucleated cells.
Nucleic Acids Res 1988; 16: 1215.
18 Ambrosone CB, Freudenheim JL, Graham S, Marshall JR, Vena JE, Brasure JR,
et al. Cytochrome P4501A1 and glutathione
S-transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk. Cancer Res 1995; 55: 3483-5.
19 de la Calle-Martin O, Fabregat V, Romero M, Soler J, Vives J, Yague J. AccII polymorphism of the
p53 gene. Nucleic Acids Res 1990;18: 4963.
20 Garte S, Boffetta P, Caporaso N, Vineis P. Metabolic gene allele nomenclature. Cancer Epidemiol Biomarkers Prev 2001; 10:
1305-6.
21 Botto, LD, Khoury MJ. Commentary: facing the challenge of gene-environment interaction:the two-by-four table and beyond. Am J
Epidemiol 2001; 153: 1016-20.
22 Irarrazabal, CE, Rojas C, Aracena R, Marquez C, Gil L. Chi-lean pilot study on the risk of lung cancer associated with codon 72
polymorphism in the gene of protein p53. Toxicol Lett 2003; 144: 69-76.
23 Huang SP, Wu WJ, Chang WS, Wu MT, Chen YY, Chen JY,
et al. p53 Codon 72 and p21 Codon 31 Polymorphisms in Prostate
Cancer. Cancer Epidemiol Biomarkers Prev 2004; 13: 2217-24.
24 Henner WD, Evans AJ, Hough KM, Harris EL, Lowe BA, Beer TM. Association of codon 72 polymorphism of p53 with lower
prostate cancer risk. Prostate 2001; 49: 263-6.
25 Seidegard J, Ekstrom G. The role of human glutathione transferases and epoxide hydrolases in the metabolism of xenobiotics. Environ
Health Perspect 1997; 105 (Suppl 4): 791-9.
26 Scheckenbach K, Lieven O, Gotte K, Bockmuhl U, Zotz R, Bier H,
et al. p53 codon 72 polymorphic variants, loss of allele-specific
transcription, and human papilloma virus 16 and/or 18 E6 messenger RNA expression in squamous cell carcinomas of the head and
neck. Cancer Epidemiol Biomarkers Prev 2004; 13 (11 Pt 1): 1805-9.
27 Dong, H, Bonala RR, Suzuki N, Johnson F, Grollman AP, Shibutani S. Mutagenic potential of benzo[a]pyrene-derived DNA adducts
positioned in codon 273 of the human P53 gene. Biochemistry 2004; 43: 15922-8.
|